Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960689 | 0.87 | KDM4E (0.56) | KDM4EMAPK1HIF1ATSHRPAOX | |
| SCHEMBL28674810 | 0.83 | TSHR (0.36) | TSHRMEN1KMT2APOLB | |
| SCHEMBL7556625 | 0.83 | KDM4E (0.39) | KDM4EMAPK1HIF1ATSHRMEN1 | |
| SCHEMBL18180992 | 0.83 | TSHR (0.44) | KDM4EMAPK1HIF1ATSHRMEN1 | |
| SCHEMBL9322077 | 0.81 | TSHR (0.40) | KDM4EMAPK1HIF1ATSHRMEN1 | |
| SCHEMBL22174072 | 0.81 | TSHR (0.52) | KDM4ETSHRMEN1KMT2AFAAH | |
| SCHEMBL16422261 | 0.79 | TSHR (0.41) | TSHRMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL18164189 | 0.79 | TSHR (0.55) | TSHRMEN1KMT2AFAAHPOLB | |
| SCHEMBL16477882 | 0.79 | MEN1 (0.61) | TSHRMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL14076038 | 0.79 | TDP1 (0.47) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002894-A1 | BIOCATALYTICAL COMPOSITIONS | INOFEA AG (CH) | 2025-01-02 | — | — | US | claimed |
| EP-4433548-A1 | BIOCATALYTICAL COMPOSITIONS | Inofea AG (CH) | 2024-09-25 | — | — | EP | claimed |
| WO-2023089035-A1 | BIOCATALYTICAL COMPOSITIONS | INOFEA AG (CH) | 2023-05-25 | — | — | WO | claimed |
| US-9879362-B2 | Method for producing nanofibers capable of storing and transferring nitric oxide and nanofibers capable of storing and transferring nitric oxide produced thereby | I-SENS, INC. (KR) | 2018-01-30 | — | — | US | claimed |
| US-9840639-B2 | Hydrophilic anti-fog coatings | INNOSENSE LLC (US) | 2017-12-12 | — | — | US | claimed |
| EP-3119845-A1 | HYDROPHILIC ANTI-FOG COATINGS | Innosense LLC (US) | 2017-01-25 | — | — | EP | claimed |
| US-20160168559-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2016-06-16 | — | — | US | claimed |
| EP-3027750-A1 | BIOCATALYTICAL COMPOSITION | Inofea GmbH (CH) | 2016-06-08 | — | — | EP | claimed |
| US-20160010241-A1 | METHOD FOR PRODUCING NANOFIBERS CAPABLE OF STORING AND TRANSFERRING NITRIC OXIDE AND NANOFIBERS CAPABLE OF STORING AND TRANSFERRING NITRIC OXIDE PRODUCED THEREBY | I-SENS, INC. (KR) | 2016-01-14 | — | — | US | claimed |
| US-20150344725-A1 | HYDROPHILIC ANTI-FOG COATINGS | KISHOLOYGOSWAMI LLC | 2015-12-03 | — | — | US | claimed |
| WO-2015148312-A1 | HYDROPHILIC ANTI-FOG COATINGS | INNOSENSE, LLC (US) | 2015-10-01 | — | — | WO | claimed |
| WO-2015014888-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2015-02-05 | — | — | WO | claimed |
| EP-4739337-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS COMPRISING PANCREATIC ENZYMES | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739336-A2 | METHOD FOR IMMOBILIZATION OF PROTEINS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739348-A1 | BIOCATALYTICAL COMPOSITIONS | Perseo Pharma AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260097103-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-2145929-A1 | Method for manufacturing redispersible, surface-modified silicon dioxide particles | Evonik Degussa GmbH (DE) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145928-A1 | Dispersion made of hydrophobic silicon dioxide particles and granulate made from same | Evonik Degussa GmbH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20080216709-A1 | CATIONICALLY STABILISED AQUEOUS SILICA DISPERSION, METHOD FOR ITS PRODUCTION AND ITS USE | BUHLER PARTEC GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1894888-A1 | Cationically stabilized aqueons silica dispersions, method for manufacture and use thereof. | Bühler Partec GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097103-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | CTRL, PREP, ANPEP | KDM4E 3283/4885MAPK1 4722/4885HIF1A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.